Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension

Phase 4

Completed

• Conditions: Stage II Hypertension

• Registration Number: NCT01070030
• Lead Sponsor: Novartis

Brief Summary

This study assessed the efficacy and safety of combination therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in patients with stage II Hypertension.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Study First Submitted: 2010-02-16
• Study First Submitted QC: 2010-02-16
• Study First Posted: 2010-02-17
• Primary Completion: 2010-10
• Study Completion: 2010-10
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-21
• Last Update Posted: 2017-02-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 230

Inclusion Criteria

• Outpatients 18 years of age or older

• Male or female patients are eligible. Female patients must be either post-menopausal for one year, surgically sterile, or using effective contraceptive methods such as oral contraceptives, barrier method with spermicidal or an intrauterine device.

• Patients with a diagnosis of hypertension as following msDBP & msSBP Requirements:

  • For newly diagnosed/untreated patients:

    • Mean Sitting Diastolic Blood Pressure (msDBP) ≥ 100 and < 120 mmHg, and/or mean sitting Systolic Blood Pressure (msSBP) ≥ 160 and < 200 mmHg at Visit1.

  • For previously treated patients with 1 or 2 antihypertensive medications:

    • msDBP ≥ 90 and < 100 mmHg, and/or msSBP ≥ 140 and < 160 mmHg at Visit 1 AND
    • msDBP ≥ 100 and < 120 mmHg, and/or msSBP ≥ 160 and < 200 mmHg at Visit 2.

  • For previously treated patients with Atenolol 50 mg once daily alone more than 2 weeks consecutively at visit 1:

    • msDBP ≥ 100 and < 120 mmHg, and/or msSBP ≥ 160 and < 200 mmHg.

• Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).

Exclusion Criteria

• Patients that previously participated in any Aliskiren study.
• Inability to receive or completely replace all previous antihypertensive medications with Atenolol 50 mg once daily for a period of 2 weeks as required by the protocol.
• Patients on 1 (other than Atenolol 50 mg once daily) or 2 antihypertensive drugs with msDBP ≥ 100 mmHg and/or msSBP ≥ 160 mmHg at Visit 1.
• Patients on 3 or more antihypertensive drugs at Visit 1.
• Pregnant or nursing (lactating) women, when pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (≥ 5 mIU/mL).
• Sexually active female patients who are not using effective contraceptive methods.
• Serum potassium <3.5 mEq/L (mmol/L) or > 5.5 mEq/L at Visit 1.
• Second or third degree heart block with or without a pacemaker, or other potentially life-threatening or symptomatic arrhythmia current or by history.
• History of noncompliance to medical regimens or unwillingness to comply with the study protocol.

Other protocol-defined inclusion/exclusion criteria may apply

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Percentage of participants with stage II hypertension achieving blood pressure (BP) goal	18 weeks	The BP goal for non-diabetic patient is defined as msSBP \< 140 mmHg and msDBP \< 90 mmHg. The BP goal for diabetic patient is msSBP \< 130 mmHg and msDBP \< 80 mmHg) in patients with stage II hypertension.

Secondary Outcome Measures

Name	Time	Method
Percentage of participants who have blood pressure surge to their baseline level during 24-h ambulatory blood pressure monitor (ABPM)	18 weeks	24-h ABPM profiles were assessed by percentage of participants who have blood pressure (BP) surge to their baseline level (during 24-h ABPM) once after patients achieve BP goal (BP goal for non-diabetic patient is defined as msSBP \< 140 mmHg and msDBP \< 90 mmHg; and the BP goal for diabetic patient is msSBP \< 130 mmHg and msDBP \< 80) at any visit only in selected study sites. The mean 24-hour MADBP (Mean Ambulatory Diastolic Blood Pressure) or MASBP (Mean Ambulatory Systolic Blood Pressure) is defined as the average of the hourly MADBP or MASBP over 24 hours respectively.
Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to study end	From baseline to study completion (between week 8 to 18)	mSBP and mDBP is defined as an average of 2 points blood pressure measurements which 5 minutes apart. Patient must be at rest for at least 5 minutes in sitting position before the heart rate and blood pressure measurement. The arm for blood pressure measurement should be the same during the whole study.
Number of participants with responder rate for Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP)	18 weeks	The responder rate of msSBP is defined as msSBP \< 140 mmHg for non-diabetic patients (msSBP \< 130 mmHg for diabetic patients) or by a reduction of ≥ 20 mmHg BP from baseline.; The responder rate of msDBP is defined as msDBP \< 90 mmHg for non-diabetic patients ( msDBP \< 80 mmHg for diabetic patients) or by a reduction of ≥ 10 mm Hg BP from baseline
Number of patients with any adverse events	18 weeks	An adverse event can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the medicinal (investigational) product.

Trial Locations

Locations (1)

Investigative Site; 🇹🇭 Nakhon Ratchasima, Thailand